153 related articles for article (PubMed ID: 29436188)
1. Peptide Nucleic Acid Clamping and Direct Sequencing in the Detection of Oncogenic Alterations in Lung Cancer: Systematic Review and Meta-Analysis.
Song JU; Lee J
Yonsei Med J; 2018 Mar; 59(2):211-218. PubMed ID: 29436188
[TBL] [Abstract][Full Text] [Related]
2. Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer.
Yoon SH; Choi YD; Oh IJ; Kim KS; Choi H; Chang J; Shin HJ; Park CK; Kim YC
Cancer Res Treat; 2015 Oct; 47(4):661-9. PubMed ID: 25715768
[TBL] [Abstract][Full Text] [Related]
3. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.
Yeo CD; Kim JW; Kim KH; Ha JH; Rhee CK; Kim SJ; Kim YK; Park CK; Lee SH; Park MS; Yim HW
Lung Cancer; 2013 Aug; 81(2):207-12. PubMed ID: 23726527
[TBL] [Abstract][Full Text] [Related]
4. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
[TBL] [Abstract][Full Text] [Related]
5. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity.
Han HS; Lim SN; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Son SM; Choi SY; Lee HC; Lee OJ
J Thorac Oncol; 2012 Feb; 7(2):355-64. PubMed ID: 22157369
[TBL] [Abstract][Full Text] [Related]
6. Reliable detection of rare mutations in EGFR gene codon L858 by PNA-LNA PCR clamp in non-small cell lung cancer.
Skronski M; Chorostowska-Wynimko J; Szczepulska E; Szpechcinski A; Rudzinski P; Orlowski T; Langfort R
Adv Exp Med Biol; 2013; 756():321-31. PubMed ID: 22836650
[TBL] [Abstract][Full Text] [Related]
7. Detection of low-level EGFR T790M mutation in lung cancer tissues.
Oh JE; An CH; Yoo NJ; Lee SH
APMIS; 2011 Jul; 119(7):403-11. PubMed ID: 21635547
[TBL] [Abstract][Full Text] [Related]
8. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
Wang MC; Wang CL; Chen TL; Chang JW; Lu JJ; Chang PY; Chiou CC
Clin Chem Lab Med; 2017 Oct; 55(12):1979-1986. PubMed ID: 28787267
[TBL] [Abstract][Full Text] [Related]
9. Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma.
Kim HS; Sung JS; Yang SJ; Kwon NJ; Jin L; Kim ST; Park KH; Shin SW; Kim HK; Kang JH; Kim JO; Park JY; Choi JE; Yoon H; Park CK; Yang KS; Seo JS; Kim YH
PLoS One; 2013; 8(12):e81975. PubMed ID: 24376508
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non-small cell lung cancer patients.
Kim I; Eom JS; Jo EJ; Mok Ki Uk J; Lee K; Uk Kim K; Park HK; Lee MK; Kim MH
Thorac Cancer; 2019 Jul; 10(7):1561-1566. PubMed ID: 31148357
[TBL] [Abstract][Full Text] [Related]
11. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M
Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448
[TBL] [Abstract][Full Text] [Related]
12. Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment response.
Park HY; Oh HJ; Kim KH; Kim TO; Park CK; Shin HJ; Lim JH; Kwon YS; Oh IJ; Kim YI; Lim SC; Kim YC; Choi YD
Thorac Cancer; 2016 Nov; 7(6):639-647. PubMed ID: 27755804
[TBL] [Abstract][Full Text] [Related]
13. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Nagai Y; Miyazawa H; Huqun ; Tanaka T; Udagawa K; Kato M; Fukuyama S; Yokote A; Kobayashi K; Kanazawa M; Hagiwara K
Cancer Res; 2005 Aug; 65(16):7276-82. PubMed ID: 16105816
[TBL] [Abstract][Full Text] [Related]
14. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
Linardou H; Dahabreh IJ; Kanaloupiti D; Siannis F; Bafaloukos D; Kosmidis P; Papadimitriou CA; Murray S
Lancet Oncol; 2008 Oct; 9(10):962-72. PubMed ID: 18804418
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
Sheng Z; Zhang Y
Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
[TBL] [Abstract][Full Text] [Related]
16. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
Han JY; Choi JJ; Kim JY; Han YL; Lee GK
BMC Cancer; 2016 Aug; 16():627. PubMed ID: 27519791
[TBL] [Abstract][Full Text] [Related]
17. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
18. Comparison of EGFR mutation detection between the tissue and cytology using direct sequencing, pyrosequencing and peptide nucleic acid clamping in lung adenocarcinoma: Korean multicentre study.
Min KW; Kim WS; Jang SJ; Choi YD; Chang S; Jung SH; Kim L; Roh MS; Lee CS; Shim JW; Kim MJ; Lee GK;
QJM; 2016 Mar; 109(3):167-73. PubMed ID: 26031706
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
